Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDIV 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 74Burkitt Lymphoma 43Neoplasm, Residual 18Leukemia 16Recurrence 14Lymphoma, Non-Hodgkin 8Leukemia, Biphenotypic, Acute 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoproliferative Disorders 6Lymphatic Diseases 5Leukemia, Lymphoid 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Immunoproliferative Disorders 4Neoplasms 3Blast Crisis 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Down Syndrome 2Bites and Stings 2Sarcoma, Myeloid 1Philadelphia-Negative ALL 1Philadelphia Chromosome 1

Interventions

rozanolixizumab 11efgartigimod alfa 10zilucoplan 8Prednisone 8Cyclophosphamide 8ravulizumab 7Rituximab 7Pyridostigmine Bromide 7telitacicept 6fludarabine 6Tacrolimus 6Mycophenolic Acid 6eculizumab 5Immunoglobulins, Intravenous 5Hizentra 4Azathioprine 4Steroids 3HBM9161 3Data Collection 3Amifampridine 3thymoglobulin 2inebilizumab 2Thymectomy 2Prednisolone 2Methylprednisolone 2Methotrexate 2Exercise 2Diagnostic Self Evaluation 2Blood Specimen Collection 2tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myasthenia Gravis × blinatumomab × Clear all
NCT06836973 2025-03-25

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Da, Yuwei, M.D.

Phase 2/3 Not yet recruiting
2 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡